Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States

被引:5
|
作者
Ginebaugh, Scott P. [1 ]
Badawi, Yomna [1 ]
Tarr, Tyler B. [1 ]
Meriney, Stephen D. [1 ]
机构
[1] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA
基金
美国国家科学基金会;
关键词
active zone; neuromuscular junction; Lambert-Eaton myasthenic syndrome; computational modeling; ACTION-POTENTIAL INITIATION; MOTOR-NERVE TERMINALS; TRANSMITTER RELEASE; PRESYNAPTIC MEMBRANE; CALCIUM-CHANNELS; PASSIVE TRANSFER; DIHYDROPYRIDINE SENSITIVITY; END-PLATE; NEUROTRANSMITTER RELEASE; SYNAPTIC-TRANSMISSION;
D O I
10.3390/biom12060740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mouse neuromuscular junction (NMJ) has long been used as a model synapse for the study of neurotransmission in both healthy and disease states of the NMJ. Neurotransmission from these neuromuscular nerve terminals occurs at highly organized structures called active zones (AZs). Within AZs, the relationships between the voltage-gated calcium channels and docked synaptic vesicles govern the probability of acetylcholine release during single action potentials, and the short-term plasticity characteristics during short, high frequency trains of action potentials. Understanding these relationships is important not only for healthy synapses, but also to better understand the pathophysiology of neuromuscular diseases. In particular, we are interested in Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune disorder in which neurotransmitter release from the NMJ decreases, leading to severe muscle weakness. In LEMS, the reduced neurotransmission is traditionally thought to be caused by the antibody-mediated removal of presynaptic voltage-gated calcium channels. However, recent experimental data and AZ computer simulations have predicted that a disruption in the normally highly organized active zone structure, and perhaps autoantibodies to other presynaptic proteins, contribute significantly to pathological effects in the active zone and the characteristics of chemical transmitters.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions
    Honnorat, Jerome
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 243 - 254
  • [2] Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome
    Tarr, Tyler B.
    Wipf, Peter
    Meriney, Stephen D.
    MOLECULAR NEUROBIOLOGY, 2015, 52 (01) : 456 - 463
  • [3] Lambert-Eaton Myasthenic Syndrome
    Kesner, Vita G.
    Oh, Shin J.
    Dimachkie, Mazen M.
    Barohn, Richard J.
    NEUROLOGIC CLINICS, 2018, 36 (02) : 379 - +
  • [4] Lambert-Eaton myasthenic syndrome
    Hernandez, Micaela A.
    Kohler, Alejandro A.
    Marrodan, Mariano
    Lautre, Andrea
    Brand, Patricio
    Nogues, Martin
    Barroso, Fabio
    REVISTA DE NEUROLOGIA, 2021, 73 (03) : 96 - 100
  • [5] Lambert-Eaton myasthenic syndrome
    Seneviratne, U
    de Silva, R
    POSTGRADUATE MEDICAL JOURNAL, 1999, 75 (887) : 516 - 520
  • [6] Lambert-Eaton myasthenic syndrome
    Mareska, M
    Gutmann, L
    SEMINARS IN NEUROLOGY, 2004, 24 (02) : 149 - 153
  • [7] Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome
    Tyler B. Tarr
    Peter Wipf
    Stephen D. Meriney
    Molecular Neurobiology, 2015, 52 : 456 - 463
  • [8] Amifampridine to treat Lambert-Eaton myasthenic syndrome
    Oh, S. J.
    DRUGS OF TODAY, 2020, 56 (10) : 623 - 641
  • [9] The Lambert-Eaton Myasthenic Syndrome: an Overview
    Kohler, Siegfried
    Meisel, Andreas
    AKTUELLE NEUROLOGIE, 2018, 45 (04) : 298 - 304
  • [10] Treatment in Lambert-Eaton myasthenic syndrome
    Maddison, Paul
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 78 - 84